Research programme: stroke therapeutics - NeuronascentAlternative Names: Stroke programme - Neuronascent
Latest Information Update: 16 Jul 2016
At a glance
- Originator Neuronascent
- Class Small molecules
- Mechanism of Action Cell differentiation stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Stroke in USA
- 13 Oct 2008 Early research in Stroke in USA (unspecified route)